Panacea Biotec Secures Exchange Approval for Reclassification of Three Jain Family Members 2 days ago
Panacea Biotec Limited has received approval from BSE and NSE to reclassify three Jain family members from 'Promoters and Promoters' Group' to 'Public' category. The reclassification, approved on July 29, 2025, applies to Mrs. Sunanda Jain, Mr. Sumit Jain, and Ms. Radhika Jain. This change does not affect the company's shareholding structure, as the reclassified members hold no shares. Promoter holding remains at 72.48% and public holding at 27.52%. The reclassification complies with SEBI regulations.
Panacea Biotec Faces Fresh GST Demand of 70.3 Million Rupees Jul 11, 2025
Panacea Biotec May Face Challenges as US Halts Support for Global Vaccine Alliance Gavi Jun 26, 2025
Panacea Biotech's Emulsipan Adjuvant Gains Recognition in CEPI Library Jun 03, 2025
Panacea Biotec Reports Q4 Net Loss of ₹19 Crore, Revenue Dips May 30, 2025
More news about Panacea Biotec
23Apr 25
Panacea Biotec Secures Additional $5.20 Million UNICEF Contract, Boosting Total Order Value to $20.15 Million
Panacea Biotec has expanded its contract with UNICEF for bivalent oral polio vaccine (bOPV) supply. The initial order of 115 million doses worth $14.95 million has been increased by an additional 40 million doses valued at $5.20 million. The total contract value now stands at $20.15 million (₹171.00 crore). The additional order will be delivered in Q3 CY2025, reinforcing the company's position in the global vaccine market and contributing to polio eradication efforts.